Multiple myeloma trials in Israel

In Israel 35 Also abroad 704

35 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Haifa, Jerusalem, Ramat Gan, Tel Aviv
Age
18 years and over
People
410 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00
Phase 1Taking people
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Where
Haifa, Jerusalem, Ramat Gan
Age
18 years and over
People
317 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05137054 · EU 2023-506247-42-00
Phase 1Taking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Where
Haifa, Jerusalem, Ramat Gan, Tel Aviv
Age
18 years and over
People
120 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT05927571 · EU 2023-504657-13-00
Phase 2Taking people
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Where
Jerusalem
Age
18 years and over
People
180
Run by
Polina Stepensky
See details and how to joinNCT06971380
Phase 2Taking people
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Haifa, Jerusalem, Ramat Gan, Tel Aviv
Age
18 years and over
People
510 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00
Phase 4Taking people
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Where
Tel Aviv
Age
18 years and over
People
295 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Where
Beersheba, Haifa, Jerusalem, Ramat Gan, Ramat Poriya, Tel Aviv
Age
18 years and over
People
400 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00
Phase 3Taking people
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Where
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
1,000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07665450
Phase 3Taking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Haifa, Jerusalem, Kfar Saba, Peatch Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 2Taking people
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Where
Afula, Ashdod, Ashkelon, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
127 worldwide
Run by
Karyopharm Therapeutics Inc
See details and how to joinNCT04414475 · EU 2024-511608-18-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Jerusalem, Ramat Gan, Tel Aviv
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00
Phase 1Taking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Haifa, Tel Aviv
Age
18 years and over
People
186 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00
Phase 1Taking people
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Where
Jerusalem, Ramat Gan, Tel Aviv
Age
18 years and over
People
127 worldwide
Run by
AbbVie
See details and how to joinNCT07409246
Phase 1Not yet taking people in Israel
Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
Where
Jerusalem
Age
18 years and over
People
160
Run by
Hadassah Medical Organization
See details and how to joinNCT07874334
Phase 1/2Taking people
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Where
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan
Age
18 years to 64 years
People
602 worldwide
Run by
AbbVie
See details and how to joinNCT06892522 · EU 2024-515770-27-00
Phase 1Taking people
Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
Where
Jerusalem
Age
18 years and over
People
60
Run by
Hadassah Medical Organization
See details and how to joinNCT07333430
No phaseTaking people
Early Detection and Screening of Hematological Malignancies - SANGUINE
Where
Tel Aviv
Age
18 years and over
People
3,000 worldwide
Run by
JaxBio Ltd
See details and how to joinNCT05735704
Phase 1/2Taking people
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Where
Jerusalem, Ramat Gan, Tel Aviv
Age
18 years and over
People
258 worldwide
Run by
Sanofi
See details and how to joinNCT04643002
Phase 3Taking people
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Where
Jerusalem
Age
18 years and over
People
183 worldwide
Run by
Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00
Phase 3Taking people
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
Haifa, Jerusalem, Ramat Gan, Tel Aviv
Age
18 years and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
Phase 3Taking people
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Where
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
1,594 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT05243797 · EU 2023-510384-36-00
No phaseTaking people
Integrative Therapies in Multiple Myeloma
Where
Haifa
Age
18 years and over
People
300
Run by
Bnai Zion Medical Center
See details and how to joinNCT06515249